TPST2 and ovarian serous cystadenocarcinoma: Patients with high expression of TPST2 demonstrated poorer prognosis compared to patients with low expression of TPST2 in breast invasive carcinoma (BRCA), head and neck squamous cell carcinoma (HNSC), ovarian serous cystadenocarcinoma (OV), sarcoma (SARC), stomach adenocarcinoma (STAD), and uterine corpus endometrial carcinoma (UCEC) (Fig. 6c).